We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nektar Therapeutics | NASDAQ:NKTR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.12 | 8.00% | 1.62 | 1.62 | 1.63 | 22,598 | 13:42:46 |
SAN FRANCISCO, March 6, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that its Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 9:20 a.m. Eastern Time.
The presentation will be accessible via a webcast link posted on the Investors section of the Nektar website at http://ir.nektar.com/. This webcast will be available for replay until April 12, 2019.
About Nektar
Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage our proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about Nektar and its drug development programs and capabilities may be found online at www.nektar.com.
View original content:http://www.prnewswire.com/news-releases/nektar-therapeutics-to-webcast-presentation-at-the-cowen-and-company-39th-annual-health-care-conference-300807958.html
SOURCE Nektar Therapeutics
Copyright 2019 PR Newswire
1 Year Nektar Therapeutics Chart |
1 Month Nektar Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions